Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05343676 Not yet recruiting - Pediatric Lymphoma Clinical Trials

Different Sonographic Modalities and PET-CT in Pediatric Lymphoma

Start date: June 1, 2022
Phase:
Study type: Observational

- To evaluate the accuracy of different sonographic modalities vs PET/CT in assessment of response to therapy in lymphoma patients: both early and late therapeutic response assessment. - To evaluate whether imaging features of pathologic lymph nodes on PET/CT and ultrasonography have a predictive role before, during and after treatment in comparison to clinical outcome.

NCT ID: NCT05343377 Not yet recruiting - Clinical trials for Extranodal Natural Killer/T-cell Lymphoma

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years. To observe the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS rate, 2-year OS rate, and CR rate in newly diagnosed ENKTCL patients; and to clarify the prognostic stratification ability of PINK-cpgE compared with PINK-E

NCT ID: NCT05341557 Not yet recruiting - Lymphoma Clinical Trials

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Start date: June 2022
Phase: Phase 1
Study type: Interventional

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.

NCT ID: NCT05340829 Recruiting - Clinical trials for AIDS Related Lymphoma and Lympholeukemia

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

Start date: March 18, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, phase I study to assess the safety and efficacy of ThisCART19A in patients with AIDS related B cell lymphoma/lympholeukemia.

NCT ID: NCT05338931 Recruiting - Clinical trials for B-cell Non Hodgkin Lymphoma

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Start date: March 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

NCT ID: NCT05338892 Completed - Clinical trials for Diffuse Large B-Cell Lymphoma

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ORCHID
Start date: June 22, 2022
Phase:
Study type: Observational

Primary Objective: To evaluate objective response rate (ORR) in adult patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) who receive systemic treatment after at least 2 prior systemic therapies in the real-world setting according to Lugano classification of malignant lymphoma (Cheson, 2014) and as assessed by independent central review Secondary Objectives: To evaluate the following outcomes in adult patients with r/r DLBCL who are treated with currently available therapies in the real-world setting: 1. ORR according to Lugano classification and as assessed by treating physician evaluation 2. Complete Response (CR) rate according to Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 3. Progression Free Survival (PFS) according to Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 4. Overall Survival (OS) 5. Duration of response (DOR) according to Lugano classification and as assessed by - Independent central review and - Treating physician evaluation 6. Disease control rate (DCR) according to Lugano classification and as assessed by: - Independent central reviewed - Treating physician evaluation 7. Time to next treatment (TTNT)

NCT ID: NCT05338879 Completed - Clinical trials for Relapsed/Refractory Follicular Lymphoma

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

FLORA
Start date: June 22, 2022
Phase:
Study type: Observational

Primary Objective: To evaluate objective response rate (ORR) in adult patients with relapsed/refractory follicular lymphoma (r/r FL) grade 1-3a who are treated with currently available therapies in the real-world setting according to Lugano classification (Cheson, 2014) of malignant lymphoma and as assessed by independent central review. Secondary Objectives: To evaluate the following outcomes in adult patients with r/r FL grade 1-3a who are treated with currently available systemic therapies in the real-world setting: 1. Objective response rate (ORR) according to the Lugano classification and as assessed by treating physician evaluation 2. Complete response (CR) rate according to the Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 3. Progression-free survival (PFS) according to the Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 4. Overall survival (OS) 5. Duration of response (DOR) according to the Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 6. Disease control rate (DCR) according to the Lugano classification and as assessed by: - Independent central review, and - Treating physician evaluation 7. Time to next treatment (TTNT) 8. Histological transformation (HT)

NCT ID: NCT05338047 Completed - Lymphoma Clinical Trials

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 clinical trial comparing time to neutrophil recovery after autotrasplant using generic pegfilgrastim vs brand-name pegfilgrastim.

NCT ID: NCT05336409 Recruiting - Clinical trials for Indolent Non-Hodgkin Lymphoma

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ELiPSE-1
Start date: January 24, 2023
Phase: Phase 1
Study type: Interventional

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

NCT ID: NCT05335018 Recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B Cell Lymphoma

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start date: May 30, 2022
Phase: Phase 2
Study type: Interventional

Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.